Dr Wendy Hague

Clinical Trials Program Director
Medicine, Sydney Medical School
NHMRC Clinical Trials Centre

Telephone +61 2 9562 5041

Map

Selected grants

2013

  • SNAC1: A randomised trial of sentinel node based management versus axillary clearance for women with small breast cancers; Gill P, Wetzig N, Ung O, Campbell I, Hague W, Farshid G; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Does bovine lactoferrin (bLF) reduce mortality and morbidity in very low birthweight infants?; Tarnow-Mordi W, Soll R, Manzoni P, Darlow B, Isaacs D, Lui K, Schofield D, Wilkinson D, Martin A, Hague W; National Health and Medical Research Council (NHMRC)/Project Grants.

2011

  • A La CaRT: Australasian phase III randomised trial comparing laparoscopic-assisted versus open resection for rectal cancer; Stevenson A, Solomon M, Hewett P, Lumley J, Fleshman J, Clouston A, Hague W; National Health and Medical Research Council (NHMRC)/Project Grants.

2009

  • Development and operational support for ALTG, ANZUP and GOGNO through the NHMRC Clinical Trials Centre: A NSW-led initiative; Stockler M, Simes R, Grimison P, Hague W; Cancer Institute New South Wales/Clinical Trials Infrastructure Grants.
  • Biostatistics, quality assurance and data systems for cancer trial groups activities based at the NHMRC Clinical Trials Centre; Gebski V, Simes R, Hague W, Gainford M, Stockler M, Goldstein D, Friedlander M, Grimison P; Cancer Institute New South Wales/Clinical Trials Infrastructure Grants.
  • An international randomised trial of low-dose aspirin to prevent recurrent venous thromboembolism (INSPIRE); Ockelford P, Brighton T, Eikelboom J, Simes R, Gallus A, Agnelli G, Kakkar A, Ockleford P, Xavier D, Hague W, Mister R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Should very premature babies receive a placental transfusion at birth? A randomised controlled trial.; Tarnow-Mordi W, Morris J, Newnham J, Hague W, Forder P, Kluckow M, Evans N, Newnham J, Osborn D, Isaacs D; National Health and Medical Research Council (NHMRC)/Project Grants.

2007

  • A phase III randomized study of brivanib Alaninate (BMS-582664) in combination with Cetuximab (Erbitux) versus placebo in combination with Cetuximab in patients previously treated with combination chemotherapy for metastatic colorectal carcinoma; Hague W; Bristol Myers Squibb/Research Support.

2006

  • Nhmrc Clinical Trials Centre Clinical Trials Methodology And Practice Consultancy, Incorporating Utilisation And Enhancement Of A Web-Based Electronic Clinical Trials Data Management System And Repository; Simes R, Keech A, Gebski V, Hague W, Stockler M; National Health and Medical Research Council (NHMRC)/Enabling Grants.

2005

  • LIPID and LIPID Cohort Studies (BMS); Simes R, Hague W, Keech A; Bristol Myers Squibb/Research Grant.
  • A Prospective, Multi-Centre, Randomised Trial of Carboplatin Flat Dosing vs Intrapatient Dose Escalation in First Line Chemotherapy of Ovarian, Fallopian Tube and Primary Peritoneal Cancers (SCOTROC4); Paul J, Hague W; Greater Glasgow Health Board/Clinical Trial.
  • A multi-national, randomised, phase III intergroup clinical trial comparing Caelyx and Carboplatin vs. Paclitaxel and Carboplatin in patients with epithelial ovarian cancer in late relapse (CALYPSO); Vasey P, Nadeau B, Pujade-Lauraine E, Hague W; Association de Recherche sur les Cancers dont Gynecologiques (ARCAGY), France on behalf of Group/Research Grants.

2004

  • International neonatal immunotherapy study (INIS): a randomised trial of intravenous immunoglobulin for neonatal sepsis; Tarnow-Mordi W, Henderson-Smart D, Hague W, Isaacs D; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Hague, W., Keech, A., Gebski, V., Pike, R. (2007). Recruitment to randomised studies. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 78-85). Sydney: AMPCo.

Journals

  • Stenson, B., Tarnow-Mordi, W., Darlow, B., Simes, R., Juszczak, E., Askie, L., Battin, M., Bowler, U., Broadbent, R., Cairns, P., Donoghoe, M., Ghadge, A., Hague, W., Kirby, A., et al (2013). Oxygen Saturation and Outcomes in Preterm Infants. The New England Journal of Medicine, 368(22), 2094-2104. [More Information]
  • Martin, A., Darlow, B., Salt, A., Hague, W., Sebastian, L., Mceill, N., Tarnow-Mordi, W. (2013). Performance of the Parent Report of Children's Abilities-Revised (PARCA-R) versus the Bayley Scales of Infant Development III. ARCHIVES OF DISEASE IN CHILDHOOD, 98(12), 955-958. [More Information]
  • Martin, A., Darlow, B., Salt, A., Hague, W., Sebastian, L., Mann, K., Tarnow-Mordi, W. (2012). Identification of infants with major cognitive delay using parental report. Developmental Medicine and Child Neurology, 54(3), 254-259. [More Information]
  • Brighton, T., Eikelboom, J., Mann, K., Mister, R., Gallus, A., Ockelford, P., Gibbs, H., Hague, W., Xavier, D., Diaz, R., Kirby, A., Simes, R. (2012). Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism. The New England Journal of Medicine, 367(2), 1979-1987. [More Information]
  • Hague, W., Forder, P., Simes, R., Hunt, D., Tonkin, A. (2003). Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: Results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. American Heart Journal, 145(4), 643-651.
  • Hague, W., Gebski, V., Keech, A. (2003). Recruitment to randomised studies. Medical Journal of Australia, 178(11), 579-581.
  • Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al (2003). Secondary prevention of cardio vascular events with long-term Pravastatin in patients with diabetes or impared fasting glucose: results from the LIPID trial. Diabetes Care, 26(10), 2713-2721.
  • Simes, R., Kirby, A., Keech, A., Hague, W., MacMahon, S., Hunt, D., Tonkin, A., Alyward, P., Colquhoun, D., Glasziou, P., et al (2002). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow up. The Lancet, 359, 1379-1387.
  • Simes, R., Marschner, C., Hunt, D., Sullivan, D., Colquhoun, D., Hague, W., Stewart, R., Keech, A., Thompson, P., White, H., et al (2002). Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation, 105(10), 1162-1169.
  • Hunt, D., Young, P., Simes, R., Hague, W., Mann, S., Owensby, D., Lane, G., Tonkin, A. (2001). Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients. Annals of Internal Medicine, (134), 931-940.
  • Simes, R., Hague, W., Young, P., Hunt, D., Mann, S., Owensby, D., Lande,, G., Tonkin, A. (2001). Benefits of pravastatin on cardiovascular events and mortalty in older patients with coronary heart disease are equpal to or exceed those seen isn younder patients: results from LIPID Trial. Annals of Internal Medicine, 134 (10), 931-940.
  • Hague, W., Emberson, J., MacMahon, S., Ried, I., Baker,, J., Tonkin, A., Hunt, D., Sharpe, N. (2001). Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a reandmised controlled trial. The Lancet, 357, 509-512.

Conferences

  • Colquhoun, D., Soderberg, S., Kirby, A., Keech, A., Simes, R., Hague, W., Hamilton-Craig, I., Tonkin, A. (2006). Obesity and adipokines as risk factors for major coronary heart disease events in patients with CHD: Results from the lipid trial. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.

2013

  • Stenson, B., Tarnow-Mordi, W., Darlow, B., Simes, R., Juszczak, E., Askie, L., Battin, M., Bowler, U., Broadbent, R., Cairns, P., Donoghoe, M., Ghadge, A., Hague, W., Kirby, A., et al (2013). Oxygen Saturation and Outcomes in Preterm Infants. The New England Journal of Medicine, 368(22), 2094-2104. [More Information]
  • Martin, A., Darlow, B., Salt, A., Hague, W., Sebastian, L., Mceill, N., Tarnow-Mordi, W. (2013). Performance of the Parent Report of Children's Abilities-Revised (PARCA-R) versus the Bayley Scales of Infant Development III. ARCHIVES OF DISEASE IN CHILDHOOD, 98(12), 955-958. [More Information]

2012

  • Martin, A., Darlow, B., Salt, A., Hague, W., Sebastian, L., Mann, K., Tarnow-Mordi, W. (2012). Identification of infants with major cognitive delay using parental report. Developmental Medicine and Child Neurology, 54(3), 254-259. [More Information]
  • Brighton, T., Eikelboom, J., Mann, K., Mister, R., Gallus, A., Ockelford, P., Gibbs, H., Hague, W., Xavier, D., Diaz, R., Kirby, A., Simes, R. (2012). Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism. The New England Journal of Medicine, 367(2), 1979-1987. [More Information]

2007

  • Hague, W., Keech, A., Gebski, V., Pike, R. (2007). Recruitment to randomised studies. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 78-85). Sydney: AMPCo.

2006

  • Colquhoun, D., Soderberg, S., Kirby, A., Keech, A., Simes, R., Hague, W., Hamilton-Craig, I., Tonkin, A. (2006). Obesity and adipokines as risk factors for major coronary heart disease events in patients with CHD: Results from the lipid trial. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.

2003

  • Hague, W., Forder, P., Simes, R., Hunt, D., Tonkin, A. (2003). Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: Results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. American Heart Journal, 145(4), 643-651.
  • Hague, W., Gebski, V., Keech, A. (2003). Recruitment to randomised studies. Medical Journal of Australia, 178(11), 579-581.
  • Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al (2003). Secondary prevention of cardio vascular events with long-term Pravastatin in patients with diabetes or impared fasting glucose: results from the LIPID trial. Diabetes Care, 26(10), 2713-2721.

2002

  • Simes, R., Kirby, A., Keech, A., Hague, W., MacMahon, S., Hunt, D., Tonkin, A., Alyward, P., Colquhoun, D., Glasziou, P., et al (2002). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow up. The Lancet, 359, 1379-1387.
  • Simes, R., Marschner, C., Hunt, D., Sullivan, D., Colquhoun, D., Hague, W., Stewart, R., Keech, A., Thompson, P., White, H., et al (2002). Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation, 105(10), 1162-1169.

2001

  • Hunt, D., Young, P., Simes, R., Hague, W., Mann, S., Owensby, D., Lane, G., Tonkin, A. (2001). Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients. Annals of Internal Medicine, (134), 931-940.
  • Simes, R., Hague, W., Young, P., Hunt, D., Mann, S., Owensby, D., Lande,, G., Tonkin, A. (2001). Benefits of pravastatin on cardiovascular events and mortalty in older patients with coronary heart disease are equpal to or exceed those seen isn younder patients: results from LIPID Trial. Annals of Internal Medicine, 134 (10), 931-940.
  • Hague, W., Emberson, J., MacMahon, S., Ried, I., Baker,, J., Tonkin, A., Hunt, D., Sharpe, N. (2001). Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a reandmised controlled trial. The Lancet, 357, 509-512.

To update your profile click here. For support on your academic profile contact .